Today: 7 February 2026
Subscribe
Browse Category

NYSE:KVUE News 14 October 2025 - 24 December 2025

Johnson & Johnson Stock After Hours Dec. 23, 2025: JNJ Slides on Record Talc Verdict — What to Know Before Wednesday’s Open

Johnson & Johnson Stock After Hours Dec. 23, 2025: JNJ Slides on Record Talc Verdict — What to Know Before Wednesday’s Open

Johnson & Johnson (NYSE: JNJ) ended Tuesday’s session lower and traded narrowly after the closing bell as investors digested a fresh—and record-size—legal headline tied to the company’s long-running talc litigation. With U.S. markets heading into a holiday-shortened session on Wednesday, December 24, the near-term setup is as much about liquidity and headline risk as it is about fundamentals. Johnson & Johnson stock price after the bell today JNJ finished regular trading on Tuesday, December 23, 2025 at roughly $205.7, down about 0.8% on the day. In extended trading, the stock was little changed to modestly higher, depending on the data
24 December 2025
·····
Kenvue Stock (KVUE) News, Forecasts and Analysis for December 23, 2025: Deal Math, Legal Headlines, and What Investors Are Watching

Kenvue Stock (KVUE) News, Forecasts and Analysis for December 23, 2025: Deal Math, Legal Headlines, and What Investors Are Watching

Kenvue Inc. (NYSE: KVUE) is trading in a very particular kind of gravity field on December 23, 2025: part consumer-health staple, part legal-headline lightning rod, and—most importantly right now—part merger-arbitrage instrument because of its pending acquisition by Kimberly-Clark. As of the latest U.S. session data available Tuesday, KVUE traded around $16.98, while Kimberly-Clark (NYSE: KMB) traded around $99.97. That matters because Kenvue shareholders are set to receive $3.50 in cash plus 0.14625 shares of Kimberly-Clark for each Kenvue share at closing, under the announced transaction terms. Kenvue Investors This structure turns KVUE into a living spreadsheet cell: every $1 move
23 December 2025
·······
Kenvue Stock (KVUE) News Today: Deal Spread Math, Kimberly-Clark Vote Timeline, Tylenol Lawsuits, and Analyst Forecasts (Dec. 19, 2025)

Kenvue Stock (KVUE) News Today: Deal Spread Math, Kimberly-Clark Vote Timeline, Tylenol Lawsuits, and Analyst Forecasts (Dec. 19, 2025)

Kenvue Inc. (NYSE: KVUE) — the consumer-health company behind Tylenol, Band-Aid, Listerine, Aveeno, and Neutrogena — is trading in a very particular kind of market right now: not just “up or down,” but “how likely is the Kimberly-Clark deal to close, and what’s the risk premium?” As of Dec. 19, 2025 (19.12.2025), KVUE last traded around $17.10. That comes right after Thursday’s close at $17.10, when the stock fell 1.04% and saw elevated trading volume, according to MarketWatch. marketwatch.com What’s moving Kenvue stock on Dec. 19, 2025 Three forces dominate the current KVUE narrative: The deal that matters: Kimberly-Clark’s acquisition
19 December 2025
······
Kenvue Stock (KVUE) Today: Latest News, Deal Outlook, Analyst Forecasts and Key Risks (Dec. 15, 2025)

Kenvue Stock (KVUE) Today: Latest News, Deal Outlook, Analyst Forecasts and Key Risks (Dec. 15, 2025)

Kenvue Inc. (NYSE: KVUE)—the consumer health company behind brands such as Tylenol, Band-Aid, Listerine, Neutrogena, and Aveeno—is trading in a market that feels less like “buy-and-hold fundamentals” and more like “event-driven probability.” The reason: Kimberly-Clark’s planned acquisition of Kenvue, a deal that has put a very visible “price anchor” on KVUE… while lawsuits, regulatory steps, and the calendar to closing keep the stock from simply snapping to the offer value. investors.kenvue.com+2Reuters+2 Below is what matters for KVUE as of Monday, December 15, 2025: where the stock is trading, what the Kimberly-Clark deal implies, the newest filings and headlines hitting screens
15 December 2025
······
Kenvue (KVUE) Stock Today: Dividend Payout, Insider Buying and Kimberly-Clark Deal in Focus – November 26, 2025

Kenvue (KVUE) Stock Today: Dividend Payout, Insider Buying and Kimberly-Clark Deal in Focus – November 26, 2025

Kenvue Inc. (NYSE: KVUE) — the Johnson & Johnson consumer-health spin‑off behind Tylenol, Listerine and Neutrogena — is back in the spotlight on Wednesday, November 26, 2025, as the stock trades higher on dividend payday, fresh insider and hedge‑fund buying disclosures, and ongoing scrutiny of its $48.7 billion sale to Kimberly‑Clark. Wikipedia+1 By early afternoon, KVUE was changing hands around $17.46, up roughly 1.6% over the past 24 hours, leaving the shares still down more than 28% over the past year and about 17% below the proposed takeover value. TradingView+1 Below is a full rundown of all Kenvue‑related news hitting
26 November 2025
·····
KVUE Stock Today (Nov. 22, 2025): Kenvue Rises as Kimberly‑Clark Deal, Dividend and Tylenol Ruling Shape Outlook

KVUE Stock Today (Nov. 22, 2025): Kenvue Rises as Kimberly‑Clark Deal, Dividend and Tylenol Ruling Shape Outlook

Published: November 22, 2025 — Information only, not investment advice. KVUE stock price today: trading below deal value but off the lows Kenvue Inc. (NYSE: KVUE) — the consumer health company behind Tylenol, Band‑Aid, Neutrogena and Listerine — is back in focus this weekend after another strong session on Friday. As of the most recent quote in late Friday trading (00:15 UTC on Saturday, November 22), KVUE last changed hands around $16.64, up roughly 3% on the day, with heavy volume of about 47 million shares. That move comes on top of a roughly 17% jump earlier this month when
22 November 2025
····
Kimberly-Clark’s $40 Billion Gamble Sends KMB Stock Plunging – What’s Next for This Dividend King?

Kimberly-Clark’s $40 Billion Gamble Sends KMB Stock Plunging – What’s Next for This Dividend King?

Real-Time Stock Price & Recent Performance As of November 4, 2025, Kimberly-Clark’s stock is trading around $102 per share, near its 52-week low. The current price reflects a dramatic sell-off that occurred on Monday, Nov 3, when KMB plunged from the high-$110s into the low $100s in a single sessionstockanalysis.com. Specifically, the stock collapsed -14.57% on Nov 3 to close at $102.27stockanalysis.com – an unusually large one-day move for a traditionally stable consumer staples stock. That wipeout followed an already soft October for the shares, which had hovered around $119-$120 in the prior weekchartmill.comchartmill.com. To put the recent action in
4 November 2025
······
Kenvue (KVUE) Stock Soars 20% on $48.7 B Buyout News – Q3 Earnings Beat and What’s Next

Kenvue (KVUE) Stock Soars 20% on $48.7 B Buyout News – Q3 Earnings Beat and What’s Next

Stock Price and Intraday Performance (Nov 3, 2025) Kenvue’s stock soared on the buyout news, delivering a sharp one-day gain. As of midday Nov. 3, KVUE traded around $17–$18, up roughly 18–20% intraday Reuters. Prior to the announcement, the stock had closed at $14.37 on Oct. 31 Stockanalysis, near its 52-week low of ~$14.02 Reuters Reuters. The takeover premium (deal valued at ~$21.01 per share) immediately boosted KVUE, though the share price remained a bit below the offer value – typical in cash/stock mergers as arbitragers factor in execution timing and Kimberly-Clark’s own stock movement (KMB shares fell ~12.5% on
3 November 2025
······
J&J Makes Bold Move: Orthopedics Spin-Off (“DePuy Synthes”) Announced – 2025 Forecast Raised

J&J Makes Bold Move: Orthopedics Spin-Off (“DePuy Synthes”) Announced – 2025 Forecast Raised

Background: J&J’s Three-Way Split Strategy Johnson & Johnson, a healthcare conglomerate, historically consisted of consumer health, pharmaceutical (Innovative Medicine), and medical technology divisions. In 2023 J&J spun off its consumer products (Tylenol, Band-Aid, Neutrogena, etc.) into a new public company, Kenvue (KVUE). Now it is moving a second business out: the orthopedics arm of its MedTech division. The spin-off means J&J will remain focused on pharmaceuticals and higher-growth medical devices, while DePuy Synthes (named after J&J’s long-time orthopedics brand) inherits the hip/knee/shoulder implant and surgical tools business reuters.com jnj.com. Spin-offs are commonly used to allow each entity to pursue tailored
14 October 2025
·····
1 2 3

Stock Market Today

Westpac share price slides after ASX rout; investors brace for next week’s WBC update

Westpac share price slides after ASX rout; investors brace for next week’s WBC update

7 February 2026
Westpac shares fell 1.2% to A$39.43 Friday as the S&P/ASX 200 dropped 2% amid broad selling. The bank is set to roll out Microsoft 365 Copilot to 35,000 staff after a pilot last year. Investors are watching for signs of loan growth and credit quality ahead of Westpac’s first-quarter update on Feb. 13. The Reserve Bank of Australia raised its cash rate to 3.85% this week.
ANZ share price fell Friday — here’s what to watch before the ASX reopens

ANZ share price fell Friday — here’s what to watch before the ASX reopens

7 February 2026
ANZ shares closed at A$37.01 on Friday, down 1.52% as the S&P/ASX 200 fell 2% and nearly $70 billion was wiped from the market. The Reserve Bank of Australia raised its cash rate by 0.25 points to 3.85%, prompting ANZ to lift variable home loan rates from Feb. 13. ANZ announced a new Salesforce-based AI CRM rollout and a board change effective Feb. 8. Investors await ANZ’s first-quarter update on Feb. 12.
Go toTop